Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care Biopsy Clear all
Terminated Not applicable Interventional

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides

NCT03789864
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Interventions
Biodynamic imaging (BDI) of mycosis fungoides
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 8, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT04462406
View directory record Official record
Conditions
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
482
States / cities
Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Completed No phase listed Observational

Prostate Biomarker Study

NCT00574899
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questioners, blood specimens, prostate tissue specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
35 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 8, 2026, 2:19 PM EDT
Terminated Not applicable Interventional

Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment

NCT02297087
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Standard of care based on target(s) identified via GWS.
Genetic
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 8, 2026, 2:19 PM EDT
Terminated Early Phase 1 Interventional

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

NCT04906382
View directory record Official record
Conditions
Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Mismatch Repair Deficiency, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer
Interventions
Biopsy, Carboplatin, Paclitaxel, Tislelizumab
Procedure · Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening

NCT01550783
View directory record Official record
Conditions
Atypical Squamous Cell of Undetermined Significance, Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Health Status Unknown, Human Papillomavirus Infection, Low Grade Cervical Squamous Intraepithelial Neoplasia, Stage 0 Cervical Cancer
Interventions
Cervical Papanicolaou Test, Cytology Specimen Collection Procedure, Questionnaire Administration, Screening Method
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Female only
Enrollment
1,335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 8, 2026, 2:19 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

NCT04929041
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
169
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Results available

MK-3475 Immunotherapy in Endometrial Carcinoma

NCT02630823
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Carcinoma, Neoplasms, Endometrial
Interventions
MK-3475, Surgical resection (standard of care), Paclitaxel (standard of care), Carboplatin (standard of care), Radiation (standard of care), Endometrial biopsy, Peripheral blood draw
Drug · Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

NCT05347407
View directory record Official record
Conditions
Parkinson Disease
Interventions
Colonoscopy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional

FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis

NCT03820934
View directory record Official record
Conditions
Psoriasis
Interventions
Fibroscan and Fibrosure
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

NCT06502691
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Interventions
Best Practice, Biopsy of Breast, Computed Tomography, Electronic Health Record Review, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Immune Checkpoint Inhibitor, Poly (ADP-Ribose) Polymerase Inhibitor, Positron Emission Tomography
Other · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation

NCT01299168
View directory record Official record
Conditions
Validation Study of Molecular Diagnostic System, Development of Reporting System for Molecular Diagnosis, Incorporate Molecular Diagnosis Into Diagnostic Standards
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • Baltimore, Maryland • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

NCT04323202
View directory record Official record
Conditions
Basal Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Tissue collection
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Early Phase 1 Interventional

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

NCT04266392
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F]-DCFPyl Ligand
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

NCT07094685
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma

NCT02968680
View directory record Official record
Conditions
Cutaneous Melanoma, Melanoma
Interventions
Sentinel Lymph Node Biopsy, Ultrasonography, Sonazoid
Procedure · Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip

NCT00868088
View directory record Official record
Conditions
Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is), Squamous Cell Carcinoma (SCC), Photodynamic Therapy (PDT), Mohs Surgery
Interventions
PDT prior to Mohs surgery
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

NCT07016399
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging
Procedure · Drug · Biological
Lead sponsor
Vandana Abramson
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 8, 2026, 2:19 PM EDT
Enrolling by invitation Not applicable Interventional

Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy

NCT07046832
View directory record Official record
Conditions
Oncology, Interventional Radiology, Liver Carcinoma, Renal Carcinoma, Biopsy
Interventions
Augmented Reality Guided Biopsy, Ultrasound Guided Biopsy
Device
Lead sponsor
MediView XR, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

GCC Agonist Signal in the Small Intestine

NCT05107219
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
Interventions
Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy, Linaclotide, Plecanatide
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Scottsdale, Arizona • Philadelphia, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

NCT07187869
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Trifecta-Heart cfDNA-MMDx Study

NCT04707872
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
MMDx diagnostic test, Prospera, HLA antibody
Diagnostic Test
Lead sponsor
University of Alberta
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Little Rock, Arkansas • Tampa, Florida • West New York, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multimedia Aid Gynecologic Counseling and Consent

NCT03899441
View directory record Official record
Conditions
Endometrium Cancer, Sentinel Lymph Node, Perioperative/Postoperative Complications
Interventions
Video
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 8, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 2:19 PM EDT